Early onset Mirror Syndrome associated with foetal sacrococcigeal teratoma: a rare entity

In the mirror syndrome, maternal symptoms mime foetal and placental oedema. The pathogenesis is unknown. The most common etiologic associations are rhesus isoimmunization, twin-twin transfusion syndrome and viral infections. Few reports are associated to foetal tumors and particularly to sacroccoccigeal teratoma (SCT). Based on several published series, foetal SCT with placentomegaly and hydrops is almost universally fatal; foetal surgery is not typically offered for hydropic foetuses beyond 26 weeks of gestational age. Delivery of the foetus is the choise treatment when mirror syndrome is present with supporting the pregnancy until delivery is necessary for maternal indications or the foetus is 30 weeks old. The management of a patient with large foetal sacrococcygeal teratoma, hydrops foetalis and early onset mirror syndrome is presented

Human papillomavirus infection in couples undergoing in vitro fertilization procedures: impact on reproductive outcomes

A prospective study was performed to assess the relationship between human papillomavirus (HPV) infection in 199 infertile couples and outcome of assisted reproductive technologies (ARTs). A highly statistically significant correlation between pregnancy loss rate (proportion of pregnancies detected by β-hCG that did not progress beyond 20 weeks) and positive HPV DNA testing in the male partner of infertile couples, compared with HPV negatives, was observed (66.7% vs. 15%

IL vaccino quadrivalente anti-HPV: efficacia e sicurezza.

La prevalenza globale del Papillomavirus (HPV) nelle neoplasie cervicali è maggiore del 90%. Il 70% delle donne si espone all'infezione da HPV almeno una volta nella vita: una su cinque può sviluppare il cancro. Il vaccino quadrivalente anti HPV 16, 18, 6 e 11 Sanofi Pasteur MSD (GARDASIL) ad azione profilattica ha come target il 70% dei casi di CIN 2/3 e di cancro cervicale, il 90% dei casi di condilomi genitali, il 30-35% dei casi di CIN. L'efficacia del vaccino è stata valutata in 4 studi clinici di fase II e III, randomizzati, in doppio cieco, verso placebo, che hanno coinvolto un totale di 20.583 donne dai 16 ai 26 anni d'età. I risultati di questo studio a 3 anni dalla sommministrazione del vaccino, hanno mostrato come il vaccino quadrivalente anti-HPV sia realmente efficace nell'impedire la formazione di CIN2/3 o AIS HPV-16/18 correlate, dimostrando quindi un'efficacia profilattica contro il cancro cervicale HPV-16/18 correlato, che rappresenta il 70% dei casi di cancro cervicale